Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA recently, continuing its progression to market. Tyra's substantial cash reserves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback